Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

3drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: abacavir ×

abacavir

This drug is selected. Its supporting articles are shown below.

Articles mentioning abacavir

3 articles · page 1 of 1

OC36 Durability of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir-based single tablet regimens in a large cohort of experienced PWH: the BIC-LASTING study

sextrans · abstract · 2026-06-05 · 1 matching annotations

88.5%

dolutegravir bictegravir emtricitabine DTG tenofovir alafenamide abacavir 3TC rilpivirine DTG-STR lamivudine

…ctegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) vs. dolutegravir (DTG)-based single tablet regimens (STR) on treatment failure-r…

P20 B/F/TAF vs DTG: similar durability, different reasons for discontinuation. results of a real-life study

sextrans · abstract · 2026-05-20 · 1 matching annotations

91.9%

Dolutegravir bictegravir darunavir abacavir atazanavir rilpivirine 3TC lamivudine emtricitabine DTG+1 more

…ain characteristics of 2359 PWH enrolled in the Bictegravir and Dolutegravir SCOLTA cohortsAbstract P20 Table 2Reasons for 568 discontinuati…

4CPS-135 Pharmacogenomics to practice’ concept: integrating pharmacogenetic data into clinical decision support for hospital pharmacists

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

92.7%

prasugrel abacavir codeine ticagrelor clopidogrel SLCO1B1 DPYD–fluoropyrimidines percutaneous coronary intervention Adverse drug reactions European Medicines Agency+6 more

…:CYP2C19–clopidogrel: in poor/intermediate metabolisers, prefer prasugrel or ticagrelor after percutaneous coronary intervention.HLA–B*57…